GlassScriptPhysician profile
Sati Patel
NPI 1013370659
$2,933.97
in general payments reported to CMS, 2019-2025
21 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $98.06 · 2022: $145 · 2023: $989 · 2024: $1,150 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,690.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $671.85 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $458.36 | 2022-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $297.77 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $203.45 | 2022-2025 | Repatha, Repatha |
| Edwards Lifesciences Corporation | $181.36 | 2024 | |
| Heartflow, INC. | $152.53 | 2023 | Ffrct |
| Abiomed | $142.07 | 2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.56 | 2023-2024 | Lifevest |
| Inspire Medical Systems, INC. | $101.27 | 2025 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $100.37 | 2024 | Arcalyst |
| Medtronic Vascular, INC. | $98.06 | 2019 | |
| Cvrx, INC. | $88.28 | 2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $85.49 | 2022-2023 | Verquvo |
| Pfizer INC. | $78.61 | 2022-2023 | |
| Philips North America LLC | $27.90 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24.26 | 2024 | Farxiga |
| Alnylam Pharmaceuticals INC. | $21.73 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $19.62 | 2023 | Xarelto |
| Itamar Medical INC | $19.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.03 | 2024 | Jardiance |
| Glaxosmithkline, LLC. | $13.40 | 2024 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sati Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.